Researchers discover new immunotherapy combination effective at killing cancer cells

Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body's immune system detect and attack cancerous cells. Doug Mahoney's lab at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way.

"What we found is a combination of cancer therapies that complement each other in helping the immune system clear the cancer," says Mahoney, PhD, assistant professor in the departments of Microbiology, Immunology and Infectious Diseases, and Biochemistry and Molecular Biology at the Cumming School of Medicine and member of the Arnie Charbonneau Cancer and Alberta Children's Hospital Research Institutes. "Our results suggest that we've been looking at these cancer drugs the wrong way - as tumour-targeting drugs - instead of what we now feel is their most important biological role: as immune stimulating therapy."

Cancer cells are smart; they know how to hide from the body's own immune system. Cancer cells also know how to control certain immune cells. Like a cruel form of mind control, some cancerous tumours can reprogram some immune cells to "block" other immune cells from attacking, leaving the tumour free to grow.

Treatments aimed at revving up the immune system's attack on the cancer may be the most promising approach to cancer therapy since combination chemotherapy. Yet studies have shown single therapies targeting only one part of the immune system have been effective in only a small percentage of patients. Results from Mahoney's research study are consistent with many other recent findings that smart combinations of therapies are even more effective in battling some cancers.

For this study, researchers combined two therapies, each targeting a different part of the immune system. The first is an injection of a man-made virus. That injection puts the "gas on" the immune system followed by a second injection of a drug being developed as a chemotherapy. That drug stops the tumour from reprogramming immune cells.

"The combination of the drugs allowed the immune cells to do what they're supposed to. We were able to cure cancer in 20 to 60 per cent of our animal models," adds Mahoney. "It's a very promising result against two very deadly forms of cancer: an aggressive breast cancer and a rare pediatric muscle cancer."

When the researchers added a third complementary immunotherapy, the cure rate went as high as 80 to 100 per cent. Results of the study are published in Nature Communications.

"These results change a lot," says Mahoney. "What's interesting is that neither drug was developed as an immunotherapy. For nearly two decades they have been studied for their ability to directly kill cancer cells. In viewing these drugs through the lens of immunotherapy, it will impact the way we study them and try to figure out how to make them work better. From a clinical perspective, it changes the way we will try to translate these drugs," says Mahoney.

Mahoney says we'll know more about the impact this study will have on cancer patients in the next five years. His lab is one of three in the world looking at this immunotherapy combination. In the other two locations, clinical trials are about to start based on a similar results.

Dae-Sun Kim, Himika Dastidar, Chunfen Zhang, Franz J Zemp, Keith Lau, Matthias Ernst, Andrea Rakic, Saif Sikdar, Jahanara Rajwani, Victor Naumenko, Dale R Balce, Ben W Ewanchuk, Pankaj Taylor, Robin M Yates, Craig Jenne, Chris Gafuik, Douglas J Mahoney.
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
Nature Communications 8, Article number: 344 (2017). doi: 10.1038/s41467-017-00324-x.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...